Acadia Pharma (ACAD) Tops Q3 EPS by 5c, Beats on Revenue, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to Acadia Pharma (ACAD) Tops Q3 EPS by 5c, Beats on Revenue, Offers Guidance

Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview

November 2, 2023 4:05 PM EDT

- Company reports record revenues resulting from strong DAYBUE launch and growth in NUPLAZID franchise

- 3Q23 DAYBUE (trofinetide) net product sales of $66.9 million

- 3Q23 NUPLAZID® (pimavanserin) net product sales of $144.8 million

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2023.

In the third quarter, Acadia delivered record product revenue, underscoring the continued strong launch of DAYBUE for the treatment of Rett syndrome, and market share growth for the... More